Summit Therapeutics' Mixed Results and Market Impact in Oncology Trials
TL;DR Summary
A Phase 3 trial of the drug ivonescimab, which targets PD-1 and VEGF pathways, showed it delayed tumor progression in lung cancer patients but did not significantly extend survival, potentially complicating its path to FDA approval in the US. The results highlight the challenges of demonstrating survival benefits for cancer drugs, despite promising progression-free survival data.
- New Summit data could slow US approval plans for PD-1/VEGF drug BioPharma Dive
- Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down. Barron's
- Summit shows mixed results from key study of lung cancer drug statnews.com
- Ivonescimab Plus Chemo Meets PFS End Point in EGFR+ NSCLC After an EGFR TKI OncLive
- Summit’s Bispecific Misses Survival Endpoint in Global Phase III Trial but Analysts Remain Optimistic BioSpace
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
92%
731 → 56 words
Want the full story? Read the original article
Read on BioPharma Dive